Home › Ovarian Cancer › Florida
Ovarian Cancer clinical trials in Florida
83 studies for Ovarian Cancer are looking for participants at sites in Florida.
Cities in Florida
- Orlando24 studies
- Miami24 studies
- Tampa20 studies
- Jacksonville15 studies
- Sarasota14 studies
- West Palm Beach10 studies
- Miami Beach10 studies
- Cape Coral7 studies
- Gainesville6 studies
- St. Petersburg6 studies
- Fort Lauderdale5 studies
- Deltona4 studies
- Plantation4 studies
- Hollywood4 studies
- Kendall3 studies
- Deerfield Beach3 studies
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- UF Health Cancer Institute - Gainesville, Gainesville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07001748A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
- Florida Cancer Specialists Lake Nona, Orlando
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07778498Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Advent Health, Orlando
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT06915025Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- and 6 more
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Orlando Health Cancer Institute ( Site 0018), Orlando
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT07743164A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Mount Sinai Braman Comprehensive Cancer Center ( Site 0078), Miami Beach
- Sarasota Memorial Hospital ( Site 0075), Sarasota
- Florida Cancer Specialists East ( Site 7000), West Palm Beach
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06824467A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Mount Sinai Cancer Center ( Site 0029), Miami Beach
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT07318558Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Holy Cross Hospital, Fort Lauderdale
- Broward Health Medical Center, Fort Lauderdale
- UF Health Cancer Institute - Gainesville, Gainesville
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06580314A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0116, Orlando
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 9, 2026 · NCT07546500Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Research Site, Tamarac
- Research Site, Tampa
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT07851025Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Mayo Clinic Jacksonville, Jacksonville
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- Advent Health Cancer Institute, Orlando
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT06787612A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura
- Florida Cancer Specialists - Bradenton Cancer Center, Bradenton
- Morton Plant Hospital, Clearwater
- and 26 more
Recruiting
Ages 35 to 50 · Women · Updated Nov 6, 2026 · NCT04251052A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- AdventHealth Cancer Institute, Orlando
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Mayo Clinic, Jacksonville
- Genoma Research, Inc., Miami
- Orlando Health, Orlando
- and 1 more
RecruitingObservational study
Ages 18 and older · Women · Updated Nov 5, 2026 · NCT05051722A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Broward Health Medical Center, Fort Lauderdale
- Florida Cancer Specialist- South, Fort Myers
- Baptist MD Anderson Cancer Center, Jacksonville
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213804Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Florida Cancer Specialists South, Fort Myers
- USOR Florida Cancer Specialists North, St. Petersburg
- USOR Florida Cancer Specialists East, West Palm Beach
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Moffitt, Tampa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0241 - Florida Cancer Specialist - North, Altamonte Springs
- Site 0173 - Mount Sinai Medical Center, Miami Beach
- Site 0308 - Advent Health, Orlando
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 30, 2026 · NCT05128825DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA08-0, Florida City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06953089A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Florida Cancer Specialists - Lake Nona, Orlando
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Broward Health Medical Center, Fort Lauderdale
- Jupiter Medical Center, Jupiter
- Mount Sinai Medical Center, Miami Beach
- and 2 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 28, 2026 · NCT06819007Lead-212 PSV359 Therapy for Patients With Solid Tumors
- University of Miami, Miami
- Biogenix, Miami
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Oct 28, 2026 · NCT06710756A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Florida Cancer Specialists, Lake Mary
- Sylvester Cancer Center, Miami
- Mount Sinai Comprehensive Cancer Center, Miami Beach
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06161025Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Mayo Clinic Jacksonville, Jacksonville
- Moffitt Cancer Center, Tampa
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04981119A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Florida Cancer Specialists, Fort Myers
- Mayo Clinic (Florida), Jacksonville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Jupiter Medical Center /ID# 276616, Jupiter
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 20, 2026 · NCT06890338Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Research Site, Miami
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 16, 2026 · NCT07816666A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- Florida Cancer Specialists, Orlando
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07186842Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 15, 2026 · NCT07214779A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- University of Florida College of Medicine /ID# 278348, Gainesville
- Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623, Orlando
- Florida Cancer Specialists - North /ID# 278626, St. Petersburg
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Oct 13, 2026 · NCT07059845First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Florida Cancer Specialists, Sarasota
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06799065Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Miami, Miami
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Moffitt Cancer Center, Tampa
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Oct 9, 2026 · NCT06276491Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
- Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine, Miami
RecruitingHealthy volunteers welcome
Ages 50 to 74 · Women · Updated Oct 9, 2026 · NCT00539162Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Mt. Sinai Comprehensive Cancer Center, Miami
- Sarasota Memorial Health Care System, Sarasota
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 6, 2026 · NCT07225270The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
- Advent Health, Orlando
- Florida Cancer Specialists South, Port Charlotte
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Mayo Clinic in Florida, Jacksonville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.